Cargando…
Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
AIM: The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. METHODS: (a)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105838/ https://www.ncbi.nlm.nih.gov/pubmed/32258980 http://dx.doi.org/10.1002/ags3.12312 |
_version_ | 1783512485541707776 |
---|---|
author | Yoshimoto, Toshiaki Yoshikawa, Kozo Higashijima, Jun Miyatani, Tomohiko Tokunaga, Takuya Nishi, Masaaki Takasu, Chie Kashihara, Hideya Takehara, Yukako Shimada, Mitsuo |
author_facet | Yoshimoto, Toshiaki Yoshikawa, Kozo Higashijima, Jun Miyatani, Tomohiko Tokunaga, Takuya Nishi, Masaaki Takasu, Chie Kashihara, Hideya Takehara, Yukako Shimada, Mitsuo |
author_sort | Yoshimoto, Toshiaki |
collection | PubMed |
description | AIM: The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. METHODS: (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab‐associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. RESULTS: (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16 weeks and 24 days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n = 45) and patients treated with bevacizumab‐free regimens as neoadjuvant therapy (n = 59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. CONCLUSION: The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible. |
format | Online Article Text |
id | pubmed-7105838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71058382020-04-01 Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab Yoshimoto, Toshiaki Yoshikawa, Kozo Higashijima, Jun Miyatani, Tomohiko Tokunaga, Takuya Nishi, Masaaki Takasu, Chie Kashihara, Hideya Takehara, Yukako Shimada, Mitsuo Ann Gastroenterol Surg Original Articles AIM: The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. METHODS: (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab‐associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. RESULTS: (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16 weeks and 24 days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n = 45) and patients treated with bevacizumab‐free regimens as neoadjuvant therapy (n = 59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. CONCLUSION: The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible. John Wiley and Sons Inc. 2020-02-12 /pmc/articles/PMC7105838/ /pubmed/32258980 http://dx.doi.org/10.1002/ags3.12312 Text en © 2020 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yoshimoto, Toshiaki Yoshikawa, Kozo Higashijima, Jun Miyatani, Tomohiko Tokunaga, Takuya Nishi, Masaaki Takasu, Chie Kashihara, Hideya Takehara, Yukako Shimada, Mitsuo Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title | Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title_full | Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title_fullStr | Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title_full_unstemmed | Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title_short | Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
title_sort | bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105838/ https://www.ncbi.nlm.nih.gov/pubmed/32258980 http://dx.doi.org/10.1002/ags3.12312 |
work_keys_str_mv | AT yoshimototoshiaki bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT yoshikawakozo bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT higashijimajun bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT miyatanitomohiko bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT tokunagatakuya bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT nishimasaaki bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT takasuchie bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT kashiharahideya bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT takeharayukako bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab AT shimadamitsuo bevacizumabassociatedintestinalperforationandperioperativecomplicationsinpatientsreceivingbevacizumab |